U.S. Active Pharmaceutical Ingredient Cdmo Market Size & Outlook
U.S. active pharmaceutical ingredient cdmo market, 2018-2030 (US$M)
Related Markets
U.S. active pharmaceutical ingredient cdmo market highlights
- The U.S. active pharmaceutical ingredient cdmo market generated a revenue of USD 28,017.1 million in 2023 and is expected to reach USD 43,864.5 million by 2030.
- The U.S. market is expected to grow at a CAGR of 6.6% from 2024 to 2030.
- In terms of segment, traditional active pharmaceutical ingredient (traditional api) was the largest revenue generating product in 2023.
- Antibody Drug Conjugate (ADC is the most lucrative product segment registering the fastest growth during the forecast period.
Active pharmaceutical ingredient cdmo market data book summary
| Market revenue in 2023 | USD 28,017.1 million |
| Market revenue in 2030 | USD 43,864.5 million |
| Growth rate | 6.6% (CAGR from 2023 to 2030) |
| Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
| Fastest growing segment | Antibody Drug Conjugate (ADC |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC |
| Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
Other key industry trends
- In terms of revenue, U.S. accounted for 23.6% of the global active pharmaceutical ingredient cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. active pharmaceutical ingredient cdmo market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 4,931.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Active Pharmaceutical Ingredient CDMO Market Scope
Active Pharmaceutical Ingredient CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. active pharmaceutical ingredient cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 39.78% in 2023. Horizon Databook has segmented the U.S. active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. holds the largest share in North America’s market and is projected to grow at a significant rate over the forecast period. The country accounted for 97.5% of the market in 2020. Increase in outsourcing practices by pharmaceutical companies and support of CDMOs in reducing operational and capital expenses are responsible for its lucrative growth.
In addition, strong R&D practices in the country and promotion of new therapies have significantly contributed to the considerable market share held by the U.S. Growing number of clinical trials in the country further creates opportunities for active pharmaceutical ingredient CDMOs.
The cost and time involved in offshore production can reduce overall cost-effectiveness and productivity of a manufacturing process. Thus, improved productivity due to domestic manufacturing is anticipated to fuel the market.
Reasons to subscribe to U.S. active pharmaceutical ingredient cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. active pharmaceutical ingredient cdmo market databook
-
Our clientele includes a mix of active pharmaceutical ingredient cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This country databook contains high-level insights into U.S. active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. active pharmaceutical ingredient cdmo market size, by product, 2018-2030 (US$M)
U.S. Active Pharmaceutical Ingredient CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
